Léger Maxime, Perrault Tristan, Pessiot-Royer Solène, Parot-Schinkel Elsa, Costerousse Fabienne, Rineau Emmanuel, Lasocki Sigismond
Anesthesia and Intensive Care Department, University Hospital Center of Angers, Angers, France; and Department of Anesthesia and Perioperative Care, University of California-San Francisco, San Francisco, California.
Anesthesia and Intensive Care Department, University Hospital Center of Angers, Angers, France.
Anesthesiology. 2024 Apr 1;140(4):679-689. doi: 10.1097/ALN.0000000000004840.
Opioid-free anesthesia is increasingly being adopted to reduce opioid consumption, but its impact on early postoperative recovery after major surgery has not been evaluated in comparative trials. The hypothesis was that an opioid-free anesthesia protocol would enhance the early quality of recovery for patients undergoing scheduled major surgery under general anesthesia.
The SOFA study was a monocentric, randomized, controlled, assessor- and patient-blinded clinical trial conducted from July 10, 2021, to February 12, 2022. The eligible population included male and female patients undergoing scheduled major surgery, excluding bone procedures, that typically require opioids for postoperative pain management. Patients in the intervention group received a combination of at least two drugs among ketamine, lidocaine, clonidine, and magnesium sulfate, without opioids for anesthesia. The standard group received opioids. The primary outcome was early postoperative quality of recovery, assessed by Quality of Recovery-15 score at 24 h after surgery. Secondary outcomes were Quality of Recovery-15 at 48 and 72 h after surgery, incidence of chronic pain, and quality of life at 3 months.
Of the 136 randomized patients, 135 were included in the primary analysis (mean age, 45.9 ± 15.7 yr; 116 females [87.2%]; 85 underwent major plastic surgery [63.9%]), with 67 patients in the opioid-free anesthesia group and 68 in the standard group. The mean Quality of Recovery-15 at 24 h was 114.9 ± 15.2 in the opioid-free anesthesia group versus 108.7 ± 18.1 in the standard group (difference, 6.2; 95% CI, 0.4 to 12.0; P = 0.026). Quality of Recovery-15 scores also differed significantly at 48 h (difference, 8.7; 95% CI, 2.9 to 14.5; P = 0.004) and at 72 h (difference, 7.3; 95% CI, 1.6 to 13.0; P = 0.013). There were no differences in other secondary outcomes. No major adverse events were noticed.
The opioid-free anesthesia protocol improved quality of recovery after major elective surgery in a statistically but not clinically significant manner when compared to standard anesthesia.
无阿片类药物麻醉越来越多地被采用以减少阿片类药物的使用,但在比较试验中尚未评估其对大手术后早期恢复的影响。假设是无阿片类药物麻醉方案将提高接受全身麻醉下计划性大手术患者的早期恢复质量。
SOFA研究是一项单中心、随机、对照、评估者和患者双盲的临床试验,于2021年7月10日至2022年2月12日进行。符合条件的人群包括接受计划性大手术的男性和女性患者,不包括通常需要阿片类药物进行术后疼痛管理的骨科手术。干预组患者接受氯胺酮、利多卡因、可乐定和硫酸镁中至少两种药物的联合使用,不使用阿片类药物进行麻醉。标准组接受阿片类药物。主要结局是术后早期恢复质量,通过术后24小时的恢复质量-15评分进行评估。次要结局是术后48小时和72小时的恢复质量-15评分、慢性疼痛发生率以及3个月时的生活质量。
在136例随机分组的患者中,135例纳入主要分析(平均年龄45.9±15.7岁;116例女性[87.2%];85例接受大整形外科手术[63.9%]),无阿片类药物麻醉组67例,标准组68例。无阿片类药物麻醉组术后24小时恢复质量-15评分的平均值为11 .9±15.2,而标准组为108.7±18.1(差值为6.2;95%CI为0.4至12.0;P = 0.026)。术后48小时(差值为8.7;95%CI为2 .9至14.5;P = 0.004)和72小时(差值为7.3;95%CI为1 .6至13.0;P = 0.013)恢复质量-15评分也有显著差异。其他次要结局无差异。未观察到重大不良事件。
与标准麻醉相比,无阿片类药物麻醉方案在统计学上改善了大择期手术后的恢复质量,但在临床上无显著意义。